ENZC OTC
Enzolytics Inc.
1W: +0.0%
1M: +100.0%
3M: +20.0%
YTD: +100.0%
1Y: -14.3%
3Y: -99.2%
5Y: -99.5%
$0.00
-0.00 (-16.67%)
Weekly Expected Move ±62.2%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.0M
52W Range0.0002-0.001
Volume5,533
Avg Volume11,506,651
Beta0.24
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOSteven Sharabura
Employees1
SectorHealthcare
IndustryBiotechnology
IPO Date2009-04-08
Websiteenzolytics.com
2000 North Central Expressway
Plano, TX 75074
US
Plano, TX 75074
US
972 292 9414
About Enzolytics Inc.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
Latest News
No recent news
Recent Insider Trades
No insider trades found